Ribavirin Completed Phase 4 Trials for Hepatitis C Viral Infection Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT00056862Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3
NCT00192569Australian Trial in Acute Hepatitis C
NCT00203606Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C
NCT00207402Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin
NCT00207363Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC
NCT00241618Timing and Duration of Acute Hepatitis C Treatment
NCT00266318Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy
NCT00277862Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4
NCT00383864Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation.
NCT00484328Ribavirin, Its Dosing Regime
NCT00502099Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4
NCT00560690The Effect of Adding Metformin to the Treatment of Hepatitis C
NCT00993122Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients
NCT01045278Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy
NCT01756079A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)
NCT01937728Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)
NCT02156570DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)
NCT02214420SMV + SOF With/Without RBV for IFN-II Patients With CHC
NCT02601976Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population
NCT02631772LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients
NCT02992457Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection